111,092 Shares in TG Therapeutics, Inc. (NASDAQ:TGTX) Acquired by Lighthouse Investment Partners LLC

Lighthouse Investment Partners LLC acquired a new stake in TG Therapeutics, Inc. (NASDAQ:TGTX) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 111,092 shares of the biopharmaceutical company’s stock, valued at approximately $1,976,000. Lighthouse Investment Partners LLC owned about 0.07% of TG Therapeutics at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in TGTX. Ashton Thomas Private Wealth LLC bought a new stake in shares of TG Therapeutics during the second quarter worth about $35,000. DekaBank Deutsche Girozentrale acquired a new stake in TG Therapeutics during the 1st quarter worth approximately $58,000. nVerses Capital LLC grew its holdings in TG Therapeutics by 34.9% during the 2nd quarter. nVerses Capital LLC now owns 5,800 shares of the biopharmaceutical company’s stock worth $103,000 after acquiring an additional 1,500 shares during the last quarter. Lazard Asset Management LLC acquired a new position in TG Therapeutics in the 1st quarter valued at approximately $91,000. Finally, Headlands Technologies LLC acquired a new position in TG Therapeutics in the 2nd quarter valued at approximately $124,000. Institutional investors and hedge funds own 58.58% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on TGTX. HC Wainwright reissued a “buy” rating and issued a $49.00 price objective on shares of TG Therapeutics in a research note on Wednesday, September 18th. B. Riley lifted their target price on TG Therapeutics from $29.00 to $34.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. Finally, The Goldman Sachs Group increased their price target on TG Therapeutics from $18.00 to $20.00 and gave the company a “neutral” rating in a research note on Wednesday, August 7th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $31.83.

TG Therapeutics Price Performance

TGTX stock opened at $23.83 on Friday. The company has a quick ratio of 2.83, a current ratio of 3.58 and a debt-to-equity ratio of 0.58. The firm has a market cap of $3.68 billion, a price-to-earnings ratio of 103.61 and a beta of 2.21. The company’s fifty day simple moving average is $22.26 and its 200 day simple moving average is $18.57. TG Therapeutics, Inc. has a 12-month low of $6.46 and a 12-month high of $26.41.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $0.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.08. TG Therapeutics had a return on equity of 57.73% and a net margin of 27.60%. The company had revenue of $73.47 million for the quarter, compared to the consensus estimate of $65.92 million. During the same period in the previous year, the business earned ($0.34) EPS. The firm’s revenue was up 357.0% compared to the same quarter last year. On average, analysts expect that TG Therapeutics, Inc. will post 0.13 earnings per share for the current year.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.